Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Thermo Fisher Scientific Inc. (TMO), Monsanto Company (MON): Billionaire Larry Robbins’ Top Picks Beat the Market Again in Q1

Page 1 of 2

Larry RobbinsGlenview Capital posted a decent 3.5% return during the first quarter according to our returns methodology (actual results will vary) even though the gains do not exactly position the fund among the ranks of the best performing funds during the quarter either, like Kevin Kotler’s Broadfin Capital, which gained more than 60%. Our weighted returns formula is based on these funds’ long positions at the start of quarter, in companies that exceeded a market cap of $1 billion, which in Glenview’s case involved 74 holdings.


Robbins, whose net worth is $2.2 billion according to Forbes, founded Glenview in 2001 after working with renowned investors like Omega Advisors’ Leon Cooperman and Mr. Gleacher of Gleacher & Company. The fund’s investment strategy is based on scrupulous research that is grounded in both top down and bottom up approachs. The investment ideas are mostly inspired by identifying temporary factors which might be wearing down the valuation in the short run such as a change in the company’s management or the price of raw materials. These ideas could also involve new circumstances that provide an impetus to the corporation’s business model, such as a change in government regulations. The Glenview Offshore Opportunity Fund was up about 24.8% net of fees during 2014, while the Glenview Capital Opportunity Fund posted 25.25% gains during the same period. 35% of the fund’s holdings are comprised of stocks in the health care sector, while another 25% comprise the consumer discretionary sector. The fund’s most valuable positions at the end of 2014 were on Thermo Fisher Scientific Inc. (NYSE:TMO), Monsanto Company (NYSE:MON), Flextronics International Ltd. (NASDAQ:FLEX) and Tenet Healthcare Corp (NYSE:THC), which altogether represented over 20% of Glenview’s portfolio value.

Many hedge funds and other big money managers prefer to invest the largest amounts of their capital in large and mega-cap stocks because these companies allow for a much larger capital allocation, which is important taking into account that the global hedge fund industry has swollen to nearly $3.0 trillion. That’s why, if we take a look at the most popular stocks among hedge funds (we track more than 700 in our database), we won’t find any mid- or small-cap stocks there. However, our backtests of hedge funds’ equity portfolios between 1999 and 2012 revealed that the 50 most popular stocks among hedge funds underperformed the market by 7 basis points per month. However, we have found that we can combine the pricing inefficiencies among small-cap picks with hedge fund expertise and obtain significant results. This was confirmed through backtesting, and in forward tests since 2012 this strategy that involves imitating the most popular small-cap picks among hedge funds managed to provide gains of more than 132%, beating the broader market by over 80 percentage points (Click here for details).

With 11.39 million shares valued at $1.43 billion, Thermo Fisher Scientific Inc. (NYSE:TMO) was Glenview’s top holding. The company posted returns of 7.35% during the first quarter. Two other investors who also cashed in on Thermo’s gains were Andreas Halvorsen of Viking Global and Boykin Curry of Eagle Capital Management. Marc Casper, CEO at Thermo Fisher Scientific Inc. (NYSE:TMO) sold about 20,000 in an insider sales transaction this month at an average price of $131.89. His remaining holding stands at about 398,600 shares.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!